Pseudomembranous Colitis Clinical Trial
Official title:
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy
The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
Clostridium difficile is the leading cause of nosocomial diarrheal disease associated with
antibiotic therapy. This is a debilitating condition with substantial morbidity and a
mortality that may be around 2-3%. There has been an enormous increase in this disease at the
VA Medical Center during the past two years, just as has occurred at other hospitals
throughout the United States.
Currently recommended therapy for this condition is metronidazole, given orally. About 15-20%
of patients fail to respond to initial therapy with metronidazole, and another 20% relapse
after treatment. Relapses may be treated with another course of metronidazole; about one-half
will respond to this therapy. The failures are treated with oral vancomycin, but this drug
also has a failure rate of 10-20%. There is, at present, no other accepted therapy (although
some articles in the literature favor vancomycin with ingested bacteria from benign species).
Furthermore, there is a strong risk to the emergence of resistant bacteria when hospitalized
patients are treated with oral vancomycin.
Nitazoxanide is an FDA approved drug that is marketed in the U.S. and has been widely used
throughout the world to treat parasitic diseases of the gastrointestinal tract; several
million children have been treated with this drug during the past decade. Nitazoxanide has
been approved as an antiprotozoal agent for oral administration in pediatric patients, ages 1
through 11, with diarrhea. The drug acts by interfering with anaerobic metabolic pathways,
and it has been shown to have excellent in vitro activity against C. difficile. We
hypothesized that this drug was both safe and effective as an alternative in patients who
have diarrheal disease caused by C. difficile. The IRB approved a double-blind protocol to
compare metronidazole with nitazoxanide, and we have treated a total of 16 patients so far
under this protocol.
In our IRB-approved double blind study (by design, two thirds of the subjects have been
randomized to the nitazoxanide), our patients have appeared to have a good response rate --
so good, in fact, that we think that nitazoxanide may be a better drug to treat this
infection than either metronidazole or vancomycin.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00382304 -
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
|
Phase 2 | |
Completed |
NCT00304876 -
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea
|
N/A | |
Completed |
NCT03427229 -
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
|
Phase 2 | |
Completed |
NCT00106509 -
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
|
Phase 3 | |
Completed |
NCT00304369 -
Response of Clostridium Difficile Infection to Metronidazole Therapy
|
N/A | |
Completed |
NCT00304889 -
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
|
Phase 3 | |
Completed |
NCT00304408 -
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
|
Phase 4 | |
Completed |
NCT00182429 -
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
|
Phase 3 | |
Withdrawn |
NCT00304863 -
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
|
Phase 4 |